

***Collaboration.
Innovation.
Novel Technology.***

Making the World
a Healthier Place

Investor Deck

September 2024 | Nasdaq: STSS



Significant Developments

- **Founded in 2017** with a vision to develop innovative drug delivery technology for healthcare
 - Developed strong product line of patented smart safety syringe systems
 - Products are FDA, WHO and CE Mark approved and cleared for use by Pfizer and Moderna
- **April 2022:** Completed IPO and raised \$16 million
- **July 2022:** Completed acquisition of SafeGard Medical syringe manufacturing facility in Hungary
 - ISO-certified, CE-Mark approved, FDA-cleared facility, producing specialty safety syringes
 - SafeGard Medical originally began syringe operations in 1998
- **February 2024:** Received first Purchase Order from Latin American distributor
- **March 2024:** Signed Collaborative Agreement with Roncadelle Operations for Sales and Distribution
- **May 2024:** Signed Asset and Syringe Sales Agreement with Nephron
 - Purchase agreement to acquire InjectEZ manufacturing assets in SC
 - +\$200 million Sales Agreement over the next five years of operation
 - SC facility on track to begin product deliveries in the second half of 2025, with projected revenue +\$35 million for the first 12 months of sales
- **July 2024:** Signed Sales Agreement with SteriCare Solutions for over \$50 million in revenue over the 5-year agreement period
- **July 2024:** Began production on purchase orders issued for 950,000 1mL Securegard syringes. by an important Swiss-based provider of cosmetic, dental, and ophthalmic injectable therapies; product to be shipped before end of 2024

Medical Syringe Market Headlines



Eli Lilly to Buy Nexus Injectables Site *April 24, 2024*

Located in Pleasant Prairie WI, the \$100+ million FDA approved site boosts Lilly's capacity to produce injectable medicines, such as their GLP-1 class Mounjaro and Zepbound, and is expected to start production by the end of 2025. Despite doubling its manufacturing capacity, demand for these drugs continues to outpace supply.

Novo Nordisk Parent Buying Catalent to Boost Wegovy Supply *February 5, 2024*

Novo Nordisk recently scored a win in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent, a key manufacturing subcontractor of the product, for \$16.5 billion.



Glass Syringe Maker Schott Expands its US Footprint with new site in North Carolina

March 19, 2024

Amid constant drug shortages that have been made worse by weak links in the supply chain, medical glass maker Schott Pharma is looking to fill in the cracks by building a new \$371 million syringe manufacturing facility in Wilson NC.

As Drug Shortages Reach Record Highs, Regulators Weigh Next Steps *May 6, 2024*

Many injectable drugs affected by shortages are real mainstays of medical care, such as morphine, norepinephrine, and electrolytes. GLP-1 class drugs for diabetes management and weight control are in high demand and short supply.

Manufacturing Locations



EU Hungary

Size	~40k Sq Ft
Clean room	ISO 8 and ISO 7
Capabilities	<ul style="list-style-type: none"> • Injection molding • Clean room assembly • Packaging • Sterilization • Warehouse
Products	<ul style="list-style-type: none"> • Active safety syringes • Insulin safety syringes • Luer lock syringes • Syringe components

EU Brescia, Italy


Size	~60k Sq Ft
Clean room	ISO 8 and ISO 7
Capabilities	<ul style="list-style-type: none"> • Injection molding • Clean room assembly • Packaging • Warehouse • Packaging production • Spring production • CDMO
Products	<ul style="list-style-type: none"> • Passive safety syringes • PFS safety systems • CDMO

USA Columbia, SC


Size	~100k Sq Ft
Clean room	ISO 8 and ISO 7
Capabilities	<ul style="list-style-type: none"> • Injection molding • Compression molding • Clean room assembly • Washing • Packaging • Warehouse • Distribution
Products	<ul style="list-style-type: none"> • Prefillable syringes (PFS) • PFS components & packaging

Medical Syringe Market Overview

- **Syringes are classified into two main groups:**
 - **Prefillable syringes:** Made of plastic, are filled and stored like vials and disposed of after use
 - **Disposable syringes:** Provide an efficient and user-friendly method of single use drug delivery
- **The market for syringes is currently growing at 4x GDP**
 - Market is increasing due to a steady growth in the number of insured aging people with medical needs
 - The largest therapeutic areas for prefilled syringes are oncology, followed by diabetes, rheumatoid arthritis, and multiple sclerosis
- **Innovations in self-administered drug delivery devices such as Sharps' syringes**
 - Patients' preference to accept treatment at home have propelled revenue in the direct-to-consumer market over the past five years



Market	Source	2022	CAGR	2030
<i>\$ in Billions</i>				
Prefilled Syringes	Average of 5 Research Reports	\$7.1	12.9%	\$18.6
Disposable Syringes	Presence Research	\$7.1	6.0%	\$11.2
TOTAL SYRINGE MARKET		\$14.2	9.7%	\$29.8



Manufacturing Location (EU)

Farkaslyuk, Hungary

Overview	Safety and Standard Disposable Syringe Production located 2 hrs Northeast of Budapest
Size & Capacities	~40k Sq Ft / Expandable to 75k Sq Ft 45 million units Expandable to 200 million units
Clean room	ISO 8 and ISO 7
Features/ Capabilities	<ul style="list-style-type: none">• Injection Molding• Clean room assembly• Packaging• Sterilization• Warehouse
Products	<ul style="list-style-type: none">• Active safety syringe (Securegard)• Insulin safety syringe• Luer Lock syringe and components
Market serviced	Healthcare networks and Pharmacies




Sharps Technology Smart Safety Disposable Syringes




Securegard

- Ultra Low Waste
- Integrated Active Recessed Safety System
- Re-use Prevention
- FDA approved
- WHO approved
- CE Mark
- EtO sterilized
- Vial Draw Sizes 1ml -10ml
- Eco Friendly



Sologard

- Standard Luer Lock
- FDA approved
- CE Mark
- EtO sterilized
- Vial Draw Sizes 3ml -10ml




Provensa

- Ultra Low Waste
- Integrated Passive PEEK Safety System
- FDA approved
- EtO sterilized
- Vial Draw 0.30ml – 3ml



Sologard Locking +

- Ultra Low Waste
- Standard Luer Lock
- Re-use Prevention
- FDA approved
- WHO approved
- CE Mark
- EtO sterilized
- Vial Draw Sizes 3ml -10ml
- Eco Friendly



Roncadelle SafeR Syringes

MATERIAL OPTIONS
PP/COC/COP

SAFETY-ENGINEERED MECHANISMS

- Auto Disable (AD)
- Re-Use Prevention (RUP)
- Sharp Injury Protection (SIP)

EASE OF USE

SafeR® Retractable Syringe works like a classic standard syringe, easy to use without specific training required.



JUST ONE CLICK

SafeR® Retractable Syringe features a one-touch coaxial needle retraction system that automatically activates upon completion of the injection.



SteriCare Solutions Sales Agreement




SteriCare™ Solutions delivers high quality medical grade water products used throughout the world. They are experts in water and saline products that meet and exceed healthcare needs in irrigation, respiratory and prefilled flush syringes.

- **5 year supply agreement for custom 10mL polypropylene syringes produced in the Sharps EU manufacturing facility:**
 - **Shipments begin in November 2024**
 - **40 million units to be supplied in the first 12 months**
 - **At least 120 million units per year to be supplied in years 2 through 5**
- **Purchase of +500 million units over the five year period will create over \$50 million in new revenue for Sharps**
- **SteriCare orders sell out the 10mL SoloGard line, at current production capacity**
- **Current activities are focused on manufacturing product for qualifications and stability testing**

Manufacturing Location (US)

West Columbia, SC

Overview	Advanced Polymer Prefillable Syringe (PFS) production in Columbia, SC
Size	~100k Sq Ft
Clean room	ISO 8 and ISO 7
Features/ Capabilities	<ul style="list-style-type: none">• Injection Molding• Clean room assembly• Washing• Packaging• Warehouse• Distribution
Capacities	60 millions units / year Expandable up 90 million units / year
Products	<ul style="list-style-type: none">• 0.5mL-50mL COC PFS in Nest and tub packaging ready to fill (Verajex)• Butyl Rubber closure production• Component production
Market serviced	Pharmaceutical and biotech



Sharps Technology Prefillable Polymer Syringes



PFS PROVEN PROCESS

- Engineered for efficient drug containment and delivery
- Molded to exact measurements using precision molds and advanced polymer materials
- Syringes are handled in a high throughput ISO clean room on state-of-the-art automation equipment
- Syringes are siliconized with a highly accurate atomization deposition process
- Capped with industry leading advanced elastomeric component closures based on customer formulation demand
- Nested in ISO standard configurations designed to work on existing fill finish Pharma technology
- Double bagged for no touch transfer
- Terminally sterilized per ISO 11137 standards, utilizing Gamma Radiation technology

PFS DELIVERY SYSTEMS

- Clear glass like transparency
- Polymer properties provide strong moisture barrier and no alkali for improved drug stability
- High break resistance due to material properties and integrated design features
- Works with industry standard rubber components and innovative silicone free options
- PFS is strong preference in the medical industry over vial draw disposable syringes



Transformative Deal to Acquire InjectEZ Assets



Acquisition of InjectEZ Assets Paves the Way for Sharps Technology's US Leadership in PFS Market



Asset purchase agreement to acquire InjectEZ specialty copolymer syringe manufacturing assets from Nephron Pharmaceuticals in Columbia, SC signed in May 2024.

Transformative acquisition enables Sharps to commercialize its innovative copolymer prefillable syringe systems and offer them to Nephron and to the healthcare market by the second half of 2025.

Acquisition of InjectEZ assets gives Sharps full control of PFS production in a state-of-the-art facility with fully automated syringe system manufacturing, packaging, and distribution.

PFS Sales Agreement with Nephron ensures five years of production and sales of at least 25 million units of high margin PFS per year.

Manufacturing capacity allows Sharps to serve the broader healthcare market and supports Sharps' ability to increase capacity for future growth.

Roncadelle Operations Collaborative Agreement



“A driving force in R&D innovation for medical drug delivery devices over more than 20 years, with a focus on improving patient experience through minimally-invasive solutions and safer practices.”



- The Collaborative Agreement signed on March 4, 2024 expands Sharps’ American-based product market into Europe, the Middle East, Africa, and the Asia-Pacific region, and opens Roncadelle’s reach into the North and Latin American markets. It provides for the expansion of the two companies’ complementary product portfolio, to offer a full line of highly sought after technologies.
- Sharps and Roncadelle are actively pursuing opportunities for further collaboration in the co-development of prefillable syringe systems and custom auto injector components, and are targeting the manufacture of these products in the U.S.
- The company specializes in developing and manufacturing proprietary passive safety syringes; and as a Contract Development and Manufacturing Organization (CDMO), they also provide end-to-end services from design to finished products for innovative, safe drug delivery solutions.
- Roncadelle owns a 34K sq ft state of the art manufacturing facility, equipped with the latest injection molding and assembly equipment, producing 100 million units per year, giving the Sharps-Roncadelle collaboration two pharma grade manufacturing sites in Europe.
- In 2024 – 2025, the Sharps-Roncadelle collaboration is targeting a run rate to sell over 40 million disposable syringes to the healthcare market.

Recent Shareholder Letter & Proxy



- Need to establish Compliance with NASDAQ minimum bid price requirement
- Company has received the requested extension to regain compliance
- The following was considered by the Board prior to the approval recommendation:
 - We have been provided an extension to complete a reverse stock split to achieve the minimum \$1.00 NASDAQ stock price requirement.
 - If our common stock is delisted from NASDAQ, this could adversely affect the value of the securities that you hold and our trading volume, making it more difficult to buy and sell our securities.
 - On the other hand, approval of the reverse stock split should help enable us to maintain our common stock's volume and ease of trading and encourage a broad range of investors to have the opportunity to invest in our Company. This will also encourage analysts and brokers to remain interested in covering and dealing with our securities. The reverse stock split will also allow us to have more access to capital to pursue our management team's growth strategies.

Following the reverse stock split, we expect to continue to be able to raise capital to grow the Company. However, this will likely be more challenging without your vote today **"FOR"** the reverse stock split proposal.

- Reverse Stock Split Process

If the proposal is approved, after the reverse stock split, each shareholder will hold the same percentage interest in the Company as before the reverse stock split; all shareholders will simply hold fewer shares. A reverse stock split decreases the number of our outstanding shares and increases the price per share – and is a mechanism often used by companies to regain and/or maintains compliance with an exchange's "minimum bid price" listing requirement. For the purpose of regaining compliance with NASDAQ requirements, NASDAQ's minimum listing price per share is \$1.00.

In Summary - Sharps Technology



- **Sharps has a large pipeline of products already in progress, identifying future revenue sources for the business**
- **Sharps is developing a strategic plan to create the first fully dedicated polymer PFS manufacturing facility in the U.S.**
- **Sharps has developed and cultivated strategic relationships with world class manufacturing, supply, and commercial partners**
- **Sharps has signed significant Sales Agreements ensuring revenue streams for its EU and US facilities**

